Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | RTX-240 |
Synonyms | |
Therapy Description |
RTX-240 is a therapy comprised of allogeneic red blood cells (RBCs) engineered to express a fusion protein consisting of the cytokine IL-15 and the IL-15 receptor alpha and TNFSF9 (4-1BBL), which may lead to activation of immune cells and antibody-dependent cell mediated cytotoxicity (ADCC) induced tumor cell killing (NCI Drug Dictionary; Journal for ImmunoTherapy of Cancer 2020;8). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RTX-240 | RTX 240|RTX240 | RTX-240 is a therapy comprised of allogeneic red blood cells (RBCs) engineered to express a fusion protein consisting of the cytokine IL-15 and the IL-15 receptor alpha and TNFSF9 (4-1BBL), which may lead to activation of immune cells and antibody-dependent cell mediated cytotoxicity (ADCC) induced tumor cell killing (NCI Drug Dictionary; Journal for ImmunoTherapy of Cancer 2020;8). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04372706 | Phase Ib/II | RTX-240 | RTX-240 Monotherapy | Terminated | USA | 0 |